For the year ending 2025-12-31, CURX had $4,824,243 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss for the year | -4,225,106 |
| Amortization of right-of-use assets | 79,396 |
| Prepaid expenses | 6,253,298 |
| Lease liabilities | -85,210 |
| Accounts payable | -2,574 |
| Accrued expenses | 2,340 |
| Net cash used in operating activities | -10,484,452 |
| Proceeds from issuance of common stock, net of underwriting costs - ipo | 15,655,192 |
| Payment of offering costs | 346,497 |
| Net cash provided by financing activities | 15,308,695 |
| Net increase in cash | 4,824,243 |
| Cash at beginning of the year | 148,891 |
| Cash at end of the year | 4,973,134 |
Curanex Pharmaceuticals Inc (CURX)
Curanex Pharmaceuticals Inc (CURX)